reviewed april 2026|next review october 2026|88 physicians psi has verified|2974 published studies
SHLP2 (Small Humanin-Like Peptide 2)
SHLP2 (Small Humanin-Like Peptide 2) is a naturally occurring (the body's own) mitochondrial-derived peptide encoded in the 16S rRNA gene, identified as the most biologically active SHLP family member with insulin-sensitizing, cytoprotective, and neuroprotective properties in cell culture, and circulating levels that decline with age.
Evidence landscape: 2974 published studies
Published studies are limited. SHLP2 research is at the cell culture characterization stage with supporting human observational data.
- 52 Human
- 127 Animal
- 21 Reviews
- 2774 Other research
Not FDA-approved. Not in clinical development. SHLP2 is at the early research characterization stage with cell culture data only. No animal efficacy studies have been published.
Not available as a therapeutic product. Research-grade material available for laboratory use. SHLP2 is a naturally occurring (the body's own) mitochondrial peptide whose circulating levels decline with age.
SHLP2 is one of six small humanin-like peptides encoded in the mitochondrial 16S rRNA gene. It is the most biologically active SHLP, with effects on insulin sensitivity, cell survival, and neuroprotection in cell culture. A prostate cancer risk association has been documented in observational studies.
PSI Assessment
Mitochondria produce more than energy. They also produce signaling peptides, and SHLP2 is the most biologically active of six small humanin-like peptides encoded in the mitochondrial genome. In cell culture, SHLP2 improves insulin-stimulated glucose uptake, activates survival signaling, and protects neurons from beta-amyloid toxicity. Circulating levels decline with age, correlating with metabolic deterioration. An observational study found that lower SHLP2 levels correlate with increased prostate cancer risk. The biology is consistent and interesting. The gap is that no animal efficacy studies have been published, and the entire evidence base is limited to cell culture and human observational data.
Most biologically active SHLP. Insulin-sensitizing and neuroprotective in cell culture. Levels decline with age. No animal efficacy data published.
The mechanism involves STAT3 signaling activation for cell survival, enhancement of insulin-stimulated glucose uptake in adipocytes and myocytes, improvement of mitochondrial oxidative phosphorylation and cellular bioenergetics, and protection against beta-amyloid toxicity in neuronal cells. SHLP2 is encoded in the same 16S rRNA region as humanin but activates distinct signaling pathways.
What the evidence supports
SHLP2 is a confirmed mitochondrial-derived peptide encoded in the 16S rRNA gene, the same region as humanin. It enhances insulin-stimulated glucose uptake in cell models, activates STAT3 cell survival signaling, and protects against beta-amyloid toxicity in neuronal cells. Circulating levels decline with age, correlating with metabolic dysfunction. Prostate cancer risk association has been documented in observational studies.
What is not yet established
Whether exogenous SHLP2 produces metabolic or neuroprotective benefits in living organisms. No animal efficacy studies published. No human safety or pharmacokinetic data. Optimal therapeutic applications. How SHLP2 interacts with other mitochondrial-derived peptides (humanin, MOTS-c) in physiological settings.
Research Evidence
The findings below cover the insulin-sensitizing effects, the neuroprotective properties, and the prostate cancer biomarker association.
Evidence by condition
Evidence is primarily in vitro with human observational biomarker data. No animal efficacy studies have been published for SHLP2.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Cytoprotection | ||||
| Diabetes/Insulin Sensitivity | ||||
| Cancer Biomarker | ||||
| Aging Biology |
SHLP2 enhances insulin-stimulated glucose uptake in adipocytes and myocytes, activates STAT3 cell survival signaling, and improves mitochondrial oxidative phosphorylation in cell culture.
These effects make SHLP2 the most biologically active member of the SHLP family. Whether the cell culture effects translate to metabolic benefit in living organisms has not been tested.
Circulating SHLP2 levels decline with age in human subjects, correlating with metabolic dysfunction. An observational study found that lower SHLP2 levels are associated with increased prostate cancer risk.
The age-related decline parallels patterns seen with humanin and MOTS-c. The prostate cancer association is observational and does not establish causation. Whether SHLP2 is protective or simply a marker of mitochondrial health is unknown.
SHLP2 protects against beta-amyloid toxicity in neuronal cell models, suggesting a potential role in neurodegenerative disease biology similar to humanin.
The neuroprotective effect is documented in cell culture only. Humanin has more advanced neuroprotective data including animal model validation.
52 Human|127 Animal|21 Reviews
View all 2974 indexed studiesHow SHLP2 (Small Humanin-Like Peptide 2) Works
SHLP2 is a naturally occurring (the body's own) mitochondrial-derived peptide encoded in the 16S rRNA region of mtDNA. It activates STAT3 survival signaling, enhances insulin-stimulated glucose uptake, and protects neurons from beta-amyloid toxicity in cell culture.
SHLP2 is produced by mitochondria and helps protect cells from stress and damage. It improves how cells respond to insulin and shields neurons from toxic proteins. Circulating levels decline with age, correlating with metabolic deterioration.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Encoded in 16S rRNA region of mtDNA. Activates STAT3.
What is SHLP2 (Small Humanin-Like Peptide 2) being studied for?
Researchers are studying SHLP2 (Small Humanin-Like Peptide 2) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for SHLP2 (Small Humanin-Like Peptide 2) overall. This means a compound can have human studies for one condition but only animal data for another.
Cytoprotection
·Animal StudiesSHLP2 activates STAT3 cell survival signaling and protects cells from stress-induced death in culture. The most biologically active cytoprotective peptide in the SHLP family.
Limitations: All data is from cell culture. No animal model validation. Whether exogenous SHLP2 administration produces cytoprotective effects in living organisms is untested.
Diabetes/Insulin Sensitivity
·Animal StudiesEnhances insulin-stimulated glucose uptake in adipocytes and myocytes in cell culture. Circulating levels decline with age, correlating with metabolic dysfunction.
Limitations: No animal model data for metabolic benefit. The correlation between declining levels and metabolic dysfunction does not establish causation.
Cancer Biomarker
·Animal StudiesLower circulating SHLP2 levels are associated with increased prostate cancer risk in an observational study.
Limitations: Observational association only. Does not establish causation. Whether SHLP2 is protective against cancer or simply a marker of mitochondrial health is unknown.
Aging Biology
·PreclinicalCirculating levels decline with age. Part of the broader mitochondrial-derived peptide decline pattern observed with humanin and MOTS-c.
Limitations: Whether the age-related decline is causally related to aging phenotypes or simply a correlate of mitochondrial function decline is unknown.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical development. No therapeutic concept has been defined for SHLP2.
Availability: Not available as a therapeutic product. Research material available for laboratory use only. SHLP2 is a naturally occurring (the body's own) mitochondrial peptide.
Class context: SHLP2 is a naturally occurring (the body's own) peptide with no known safety concerns from normal physiology. No exogenous administration studies have been conducted in any species.
SHLP2 is a naturally occurring (the body's own) mitochondrial peptide. No safety data exists for exogenous administration because no animal or human dosing studies have been conducted.
Questions and Comparisons
Questions the evidence raises for a SHLP2 (Small Humanin-Like Peptide 2) discussion.
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Discovery paper identifying SHLP2 as a mitochondrial-derived peptide with potent cytoprotective and insulin-sensitizing properties. SHLP2 enhanced insulin-stimulated glucose uptake in cell models, reduced reactive oxygen species, and protected cells from apoptosis. Circulating SHLP2 levels declined with age in human serum samples.Cobb LJ et al., 2016 in Aging (Albany NY). View on PubMed
- 2.Prospective nested case-control study within the Multiethnic Cohort measuring pre-diagnostic SHLP2 levels in men who later developed prostate cancer. Higher circulating SHLP2 was associated with reduced prostate cancer risk, particularly for aggressive disease, suggesting a protective role for this mitochondrial peptide in cancer biology.Mehta HH et al., 2020 in Aging Cell. View on PubMed
- 3.Comprehensive review of the SHLP family and humanin in aging contexts. SHLP2 emerged as the strongest metabolic regulator in the family, with effects on insulin sensitivity, mitochondrial function, and cellular stress resistance. The review consolidated evidence that SHLP2 decline may contribute to age-related metabolic deterioration.Kim SJ et al., 2019 in Aging Cell. View on PubMed
- 4.Study comparing mitochondrial peptide effects in retinal cells under oxidative stress. SHLP2 provided significant protection against mitochondrial membrane depolarization and reduced senescence markers, with potency comparable to humanin in maintaining mitochondrial function under stress conditions.Sreekumar PG et al., 2021 in Cell Death Discov. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.